PsyRX, an Israeli pharmaceutical startup, is pioneering a next-generation treatment for depression that combines the benefits of an SSRI (a common antidepressant) with Ibogaine, a natural psychedelic stimulant.
This innovative approach aims to provide faster relief from depression while reducing common SSRI side effects like weight gain and sexual dysfunction.
Globally, depression affects over 5% of adults, according to the World Health Organization.
Traditional SSRIs often take up to 8 weeks to work, leading many patients to stop treatment prematurely. By combining an SSRI with Ibogaine, PsyRX’s treatment is designed to take effect sooner, offering hope to millions who need immediate relief.
PsyRX is seeking funding to begin human trials in 2025.
This Israeli innovation exemplifies how the nation’s technological advancements can offer new solutions for global challenges.
For more information, visit PsyRX.co or the PsyRX project page on Exit Valley.
Click here to visit the PsyRX project page on Exit Valley
PHOTO: Prof. Itamar Grotto PsyRx's chairman